Indication

TRISENOX® (arsenic trioxide) injection is indicated for induction of remission and consolidation in patients with acute promyelocytic leukemia (APL) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.

Refer to the full Prescribing Information, including Boxed Warnings.

Sign up for updates and
more information about
TRISENOX and relapsed/
refractory APL

Focus
your search:

I am a:

  • A treatment goal for
    relapsed/refractory APL

    Understand the role of
    RT-PCR in identifying
    relapsed/refractory APL

  • Complete and molecular
    remission rates for
    TRISENOX

    See efficacy data
    from a clinical trial
    on TRISENOX

  • Safety data from a
    TRISENOX clinical trial

    See adverse event rates
    from a clinical trial
    on TRISENOX

  • Important Safety
    Information

    Read the Important
    Safety Information,
    including Boxed Warnings

  • Monitoring guidelines for
    relapsed/refractory APL

    Review NCCN and
    International Working Group
    monitoring guidelines

  • TRISENOX dosing and
    administration

    Recommended dosing
    for induction and
    consolidation

  • Patient monitoring
    considerations
    for TRISENOX

    Important guidelines for
    monitoring and managing
    adverse events

  • Watch:
    About TRISENOX

    This video covers a range
    of topics relevant to
    TRISENOX

  • Physician, nurse, and
    patient support materials

    Helpful resources for your
    patients and your
    practice

  • TRISENOX clinical
    study design

    See dosing and patient
    characteristics in the
    TRISENOX clinical trial

  • Risk factors for
    relapsed/refractory APL

    See what risk factors to
    watch for

  • Prevalence of
    relapsed/refractory APL

    See how frequently
    relapsed/refractory
    APL occurs

  • Patient checklist for
    TRISENOX Patient checklist for TRISENOX

    A downloadable PDF to
    help you monitor and
    manage adverse events

  • Watch:
    What nurses have to say

    Nurses share their
    perspectives and
    experiences

  • TRISENOX mechanism
    of action

    See the two ways
    TRISENOX is thought
    to work

  • Watch:
    Genetics and Pathology of
    relapsed/refractory APL

    This video explains the
    pathophysiology of
    relapsed/refractory APL

  • Reimbursement assistance
    and support

    Helping patients and
    providers with the
    reimbursement process

TO REPORT SIDE EFFECTS:

Contact us at 1-800-896-5855
or USMedInfo@tevapharm.com

CONTACT US:

Teva Pharmaceuticals
41 Moores Road
Frazer, PA 19355 USA

1-610-344-0200

www.tevausa.com
Contact Teva
Product Information Request

MEDICAL INFORMATION:

For healthcare professionals or patients with specific medical questions about TRISENOX, please contact us at:

Teva Medical Information
1-800-896-5855

Mon–Fri, 9:00 AM to 7:00 PM ET

USMedInfo@tevapharm.com

Sign up for updates and
more information about
TRISENOX and relapsed/
refractory APL

Teva Oncology Logo
©2015 Cephalon, Inc., a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd. All rights reserved. The
information presented on this Web site is intended for US residents only. TRI-40128. May 2015.

WARNING: APL DIFFERENTIATION SYNDROME, CARDIAC CONDUCTION ABNORMALITIES, AND ELECTROLYTE MONITORING

APL Differentiation Syndrome: Patients with APL treated with TRISENOX have experienced symptoms similar to a syndrome called the retinoic-acid-Acute Promyelocytic Leukemia (RA-APL) or APL differentiation syndrome, characterized by fever, dyspnea, weight gain, pulmonary infiltrates and pleural or pericardial effusions, with or without leukocytosis. This syndrome can be fatal. High-dose steroids have been administered at the first suspicion of the APL differentiation syndrome and appear to mitigate signs and symptoms. At the first signs that could suggest the syndrome (unexplained fever, dyspnea and/or weight gain, abnormal chest auscultatory findings or radiographic abnormalities), immediately initiate high-dose steroids (dexamethasone 10 mg intravenously BID), irrespective of the leukocyte count, and continue for at least 3 days or longer until signs and symptoms have abated. The majority of patients do not require termination of TRISENOX therapy during treatment of the APL differentiation syndrome.
Cardiac Conduction Abnormalities: Before initiating therapy, perform a 12-lead ECG, assess serum electrolytes and creatinine, correct preexisting electrolyte abnormalities, and consider discontinuing drugs known to prolong QT interval. Arsenic trioxide can cause QT interval prolongation and complete atrioventricular block. QT prolongation can lead to a torsade de pointes-type ventricular arrhythmia, which can be fatal. The risk of torsade de pointes is related to the extent of QT prolongation, concomitant administration of QT prolonging drugs, a history of torsade de pointes, preexisting QT interval prolongation, congestive heart failure, administration of potassium-wasting diuretics, or other conditions that result in hypokalemia or hypomagnesemia. One patient (also receiving amphotericin B) had torsade de pointes during induction therapy for relapsed APL with arsenic trioxide.
Contraindications: TRISENOX is contraindicated in patients who are hypersensitive to arsenic.
APL Differentiation Syndrome: Nine of 40 patients with APL treated with TRISENOX, at a dose of 0.15 mg/kg, experienced the APL differentiation syndrome.
Cardiac Conduction Abnormalities: Torsade de Pointes, Complete Heart Block, and QT Prolongation: Sixteen of 40 patients (40%) had at least one ECG tracing with a QTc interval greater than 500 msec. Prolongation of the QTc was observed between 1 and 5 weeks after TRISENOX infusion, and then returned towards baseline by the end of 8 weeks after TRISENOX infusion. Monitor ECG weekly and more frequently for clinically unstable patients. For QTc greater than 500 msec, complete corrective measures and reassess the QTc with serial ECGs prior to initiating TRISENOX. During TRISENOX therapy, maintain potassium concentrations above 4 mEq/L and magnesium concentrations above 1.8 mg/dL. Reassess patients who reach an absolute QT interval value > 500 msec and immediately correct concomitant risk factors, if any, while the risk/benefit of continuing versus suspending TRISENOX therapy should be considered. The risk may be increased when TRISENOX is coadministered with medications that can lead to electrolyte abnormalities (such as diuretics or amphotericin B).
Carcinogenesis: The active ingredient of TRISENOX, arsenic trioxide, is a human carcinogen. Monitor patients for the development of second primary malignancies.
Embryo-Fetal Toxicity: TRISENOX can cause fetal harm when administered to a pregnant woman. One patient who became pregnant while receiving arsenic trioxide had a miscarriage. Advise pregnant women of the potential risk to a fetus. Advise females and males of reproductive potential to use effective contraception during and after treatment with TRISENOX.
Lactation: TRISENOX is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants, discontinue breastfeeding during treatment with TRISENOX.
Laboratory Tests: Electrolyte and glucose levels, as well as hepatic, renal, hematologic, and coagulation profiles should be monitored at least twice weekly, and more frequently for clinically unstable patients during the induction phase and at least weekly during the consolidation phase.
Drug Interactions: Avoid the concomitant use of TRISENOX with medications that can prolong the QT/QTc interval or those that can lead to electrolyte abnormalities. Concomitant use of drugs that can prolong the QT/QTc interval with TRISENOX may increase the risk of serious QT/QTc interval prolongation. Electrolyte abnormalities increase the risk of serious QT/QTc interval prolongation. Monitor ECGs and electrolytes more frequently in patients who are unable to avoid concomitant use of these medications and TRISENOX.
Pediatric Use: In a pediatric study, the toxicity profile observed in 13 pediatric patients with APL between the ages of 4 and 20 receiving TRISENOX was similar to that observed in adult patients. Additional drug-related toxicities reported included: gastrointestinal disorders, metabolic and nutrition disorders, respiratory disorders, cardiac failure congestive, neuralgia, and enuresis. One case each of pulmonary edema and caecitis were considered serious reactions. No children less than 4 years of age were enrolled in the trial due to the rarity of APL in this age group.
Patients with Renal Impairment: Exposure of arsenic trioxide may be higher in patients with severe renal impairment. Patients with severe renal impairment (creatinine clearance less than 30 mL/min) should be monitored for toxicity when these patients are treated with TRISENOX, and a dose reduction may be warranted. The use of TRISENOX in patients on dialysis has not been studied.
Patients with Hepatic Impairment: Since limited data are available across all hepatic impairment groups, caution is advised in the use of TRISENOX in patients with hepatic impairment. Monitor patients with severe hepatic impairment (Child-Pugh Class C) who are treated with TRISENOX for toxicity.
Most Common Adverse Reactions: Most patients experienced some drug related toxicity, most commonly leukocytosis, gastrointestinal (nausea, vomiting, diarrhea, and abdominal pain), fatigue, edema, hyperglycemia, dyspnea, cough, rash or itching, headaches, and dizziness. These adverse effects have not been observed to be permanent or irreversible nor do they usually require interruption of therapy.